DK5188D0 - Antistof-folinsyreanalogkonjugat, dets fremstilling, samt ved fremstillingen anvendeligt mellemprodukt og fremstilling deraf - Google Patents

Antistof-folinsyreanalogkonjugat, dets fremstilling, samt ved fremstillingen anvendeligt mellemprodukt og fremstilling deraf

Info

Publication number
DK5188D0
DK5188D0 DK005188A DK5188A DK5188D0 DK 5188 D0 DK5188 D0 DK 5188D0 DK 005188 A DK005188 A DK 005188A DK 5188 A DK5188 A DK 5188A DK 5188 D0 DK5188 D0 DK 5188D0
Authority
DK
Denmark
Prior art keywords
antibody
conjugates
folic acid
manufacturing
vivo
Prior art date
Application number
DK005188A
Other languages
English (en)
Other versions
DK5188A (da
Inventor
Daniel J Coughlin
Robert D Radcliffe
Anthony Dwight Lopes
John D Rodwell
Original Assignee
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogen Corp filed Critical Cytogen Corp
Publication of DK5188D0 publication Critical patent/DK5188D0/da
Publication of DK5188A publication Critical patent/DK5188A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
DK005188A 1986-05-08 1988-01-07 Antistof-folinsyreanalogkonjugat, dets fremstilling, samt ved fremstillingen anvendeligt mellemprodukt og fremstilling deraf DK5188A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86103786A 1986-05-08 1986-05-08
PCT/US1987/000992 WO1987006837A1 (en) 1986-05-08 1987-05-01 Antibody conjugates of amine derivatives of folic acid analogs

Publications (2)

Publication Number Publication Date
DK5188D0 true DK5188D0 (da) 1988-01-07
DK5188A DK5188A (da) 1988-04-15

Family

ID=25334695

Family Applications (1)

Application Number Title Priority Date Filing Date
DK005188A DK5188A (da) 1986-05-08 1988-01-07 Antistof-folinsyreanalogkonjugat, dets fremstilling, samt ved fremstillingen anvendeligt mellemprodukt og fremstilling deraf

Country Status (11)

Country Link
EP (1) EP0251455B1 (da)
JP (1) JP2564586B2 (da)
AT (1) ATE105484T1 (da)
AU (1) AU7359087A (da)
CA (1) CA1330378C (da)
DE (1) DE3789788T2 (da)
DK (1) DK5188A (da)
ES (1) ES2051738T3 (da)
FI (1) FI880059A (da)
WO (1) WO1987006837A1 (da)
ZA (1) ZA873305B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK8189A (da) * 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
US5028697A (en) * 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5144012A (en) * 1988-08-08 1992-09-01 Eli Lilly And Company Cytotoxic drug conjugates
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
JPH04504248A (ja) * 1988-09-30 1992-07-30 ネオロクス　コーポレーション シッフ塩基で結合した、ターゲティング物質―診断／治療薬複合体
AU633538B2 (en) * 1988-11-18 1993-02-04 Regents Of The University Of California, The Conjugated polypeptides and methods for their preparation and use
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
US5208008A (en) * 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
DE59709788D1 (de) 1997-05-09 2003-05-15 Deutsches Krebsforsch Konjugat, umfassend einen Folsäureantagonisten und einen Träger
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
JP6744227B2 (ja) 2014-02-21 2020-08-19 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 糖標的化治療剤
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10246410B2 (en) 2014-12-03 2019-04-02 Life Technologies Corporation Hydrazinyl and aminooxy compounds and their methods of use
US10309959B2 (en) 2014-12-03 2019-06-04 Life Technologies Corporation Charged reactive oligomers
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1595101A (en) * 1977-03-15 1981-08-05 Hoffmann La Roche Enzyme modifier immunoassay
FR2402664A1 (fr) * 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4584375A (en) * 1984-08-21 1986-04-22 Rensselaer Polytechnic Institute Fluorine-containing antifolates incapable of polyglutamate formation
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates

Also Published As

Publication number Publication date
FI880059A0 (fi) 1988-01-07
DE3789788D1 (de) 1994-06-16
ZA873305B (en) 1987-11-02
WO1987006837A1 (en) 1987-11-19
DK5188A (da) 1988-04-15
ATE105484T1 (de) 1994-05-15
JP2564586B2 (ja) 1996-12-18
FI880059A (fi) 1988-01-07
EP0251455A3 (en) 1990-09-05
EP0251455B1 (en) 1994-05-11
AU7359087A (en) 1987-12-01
ES2051738T3 (es) 1994-07-01
CA1330378C (en) 1994-06-21
DE3789788T2 (de) 1994-08-18
JPS63503144A (ja) 1988-11-17
EP0251455A2 (en) 1988-01-07

Similar Documents

Publication Publication Date Title
DK5188A (da) Antistof-folinsyreanalogkonjugat, dets fremstilling, samt ved fremstillingen anvendeligt mellemprodukt og fremstilling deraf
DE3853792D1 (de) Amin-Derivate von Anthracyclin-Antibiotika.
FI981807A (fi) Menetelmä terapeuttisesti käyttökelpoisten starburst-konjugaattien valmistamiseksi
NO885199D0 (no) FremgangsmŸte for fremstilling av monoklonale antistoffkonjugater.
NO20005337D0 (no) Polyol-IFN-<BETA>-konjugater
DE69333107T2 (de) Dualer träger für immunogene konstrukte
ATE150321T1 (de) Anthracyclin-konjugate mit einem neuen linker und verfahren zu dessen herstellung
DK148586A (da) Fremgangsmaade til fremstilling af konjugater af metal-lothionein og biologisk aktive molekyler
ES2064613T3 (es) Produccion de agentes citotoxicos.
FI104234B1 (fi) Menetelmä vasta-ainekonjugaattien valmistamiseksi neoplastisten sairauksien hoitoon
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
ATE2423T1 (de) 1-acyloxyphenyl-1,2-diphenylalken-derivate, verfahren zu deren herstellung und eine diese derivate enthaltende pharmazeutische zusammensetzung.
DE60121035T2 (de) Impfstoff zur Behandung von Nikotinabhängigkeit
ATE1150T1 (de) Anthracyclinglycosiden, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen.
DE69228869D1 (de) Stabilisierte antikörperfragmente

Legal Events

Date Code Title Description
AGE Re-establishment of rights: approved
AHB Application shelved due to non-payment